https://www.thebodypro.com/tag/id-week

IDWeek

The Latest

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds Img

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds

Many people who had high lipid levels while taking common HIV treatment regimens that included a protease inhibitor, such as Prezista or Reyataz, saw remarkable improvements after the switch.

Suicide Risk Doubles Among HIV-Infected People Taking Efavirenz, Study Finds Img

Suicide Risk Doubles Among HIV-Infected People Taking Efavirenz, Study Finds

Mental health _really_ matters in HIV. We got a hugely important reminder of that this month in the form of new research regarding suicide and Sustiva (one of the drugs in Atripla).

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It? Img

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

A single drug dose, taken no more than once a month, to treat HIV: It's no longer the stuff of idle fantasy. But in a world stuffed with excellent once-a-day drugs, will long-acting meds have value?

Vicks Vaporub Works as Treatment for Foot Fungus in HIV-Infected Individuals, Study Finds Img

Vicks Vaporub Works as Treatment for Foot Fungus in HIV-Infected Individuals, Study Finds

Vicks VapoRub may be a cheap, effective and safe topical treatment for foot fungus (also known as onychomycosis) among people living with HIV, according to results from a pilot study presented at ID Week 2012. Onychomycosis is common in both the gen...

Six Promising HIV Drugs in the Pipeline Img

Six Promising HIV Drugs in the Pipeline

What new HIV medications do we have to look forward to over the next few years? How will these newer drugs improve upon the older ones? To shed some light on these questions, Roy Gulick, M.D., recently provided an overview of some of our star HIV dru...

Toward an HIV Cure: Overview and Latest Strategies Img

Toward an HIV Cure: Overview and Latest Strategies

How close are we to an HIV cure? What have we learned from the precious few "functional cure" cases out there, and what other interventions are being developed? To answer these questions, Joseph Eron, M.D., director of the University of North Caroli...

CD4 Nadir Not a Predictor of Pneumonia After Starting HIV Treatment, Study Finds Img

CD4 Nadir Not a Predictor of Pneumonia After Starting HIV Treatment, Study Finds

People with HIV face an increased pneumonia risk even after they've started HIV treatment. However, a recent study suggests that risk isn't affected by how suppressed the immune system was prior to starting treatment.

Pilot Program Increases Cervical Cancer Screening by 42% Among Women Living With HIV Img

Pilot Program Increases Cervical Cancer Screening by 42% Among Women Living With HIV

Because women with HIV have higher rates of cervical cancer than HIV-negative women, cervical cancer screening should be performed annually. However, many women never get screened. Here's how a program in St. Louis reversed the trend.

Black MSM Caught in HIV's Net by Complex Web of Factors Img

Black MSM Caught in HIV's Net by Complex Web of Factors

African-American men who have sex with men (MSM) remain disproportionately affected by the HIV epidemic in the U.S., but the causes of and solutions to this disparity defy easy definition, according to Greg Millett, M.P.H., of the U.S. Centers for Di...

Trip Gulick's Parody of "Do-Re-Mi" Featuring the HIV Antiretroviral Pantheon (Lyrics) Img

Trip Gulick's Parody of "Do-Re-Mi" Featuring the HIV Antiretroviral Pantheon (Lyrics)

Roy M. "Trip" Gulick, M.D., a professor of medicine and the chief of the Division of Infectious Diseases at Weill Medical College of Cornell University, took the stage at the opening session of the inaugural IDWeek conference to accept the HIV Medici...